Drug Guidance for Subsidy 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teripa... See all × 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teriparatide for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and Teriparatide for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
SUBCUTANEOUS Select a brand starting with the letter: T TERIPARATIDE-TEVA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20 MCG/80 MCL [SIN17077P]